12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ruconest conestat alfa regulatory update

Pharming said EMA granted approval to allow contract manufacturing organization Sanofi Chimie to manufacture Ruconest conestat alfa to treat acute attacks of hereditary angioedema (HAE) at its Aramon, France, site....

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >